Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

RYTM

Rhythm Pharmaceuticals Inc

Feb 12 • 03:35PM ET

96.31

-2.16 -2.20 %

Healthcare • Biotechnology • USA • NASD

Peers: PFE VRTX MRK NVO SNY LLY TAK VTRS XENE NBIX

| Held by: VTI VB IWM XBI VBK VXF IBB IWO SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-3.10	Insider Own	6.74%	Shs Outstand	66.68M	Perf Week	-7.28%
Market Cap	6.43B	Forward P/E	-	EPS next Y	-2.70	Insider Trans	-2.55%	Shs Float	62.24M	Perf Month	-10.66%
Enterprise Value	6.27B	PEG	-	EPS next Q	-0.80	Inst Own	107.27%	Short Float	10.02%	Perf Quarter	-3.56%
Income	-197.71M	P/S	36.87	EPS this Y	26.89%	Inst Trans	5.14%	Short Ratio	8.25	Perf Half Y	-1.59%
Sales	174.33M	P/B	43.16	EPS next Y	14.89%	ROA	-44.19%	Short Interest	6.24M	Perf YTD	-10.03%
Book/sh	2.23	P/C	15.45	EPS next 5Y	-	ROE	-240.36%	52W High	122.20 -21.19%	Perf Year	67.09%
Cash/sh	6.23	P/FCF	-	EPS past 3/5Y	-45.66% -2.34%	ROIC	-49.11%	52W Low	45.90 109.80%	Perf 3Y	246.81%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	245.54% -	Gross Margin	89.05%	Volatility	5.91% 5.32%	Perf 5Y	219.54%
Dividend TTM	-	EV/Sales	35.97	EPS Y/Y TTM	28.47%	Oper. Margin	-106.81%	ATR (14)	5.41	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.53	Sales Y/Y TTM	54.92%	Profit Margin	-113.41%	RSI (14)	37.65	Recom	1.12
Dividend Gr. 3/5Y	- -	Current Ratio	4.75	EPS Q/Q	-11.52%	SMA20	-7.38%	Beta	2.05	Target Price	141.57
Payout	-	Debt/Eq	1.75	Sales Q/Q	54.28%	SMA50	-9.22%	Rel Volume	1.23	Prev Close	98.47
Employees	283	LT Debt/Eq	1.71	Earnings	Nov 04 BMO	SMA200	4.49%	Avg Volume	755.71K	Price	96.31
IPO	Oct 05, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	-15.80% 1.16%	Trades		Volume	869,398	Change	-2.20%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-25-25	Initiated	Citigroup	Buy	$136
Nov-05-25	Downgrade	Oppenheimer	Outperform → Perform
Jul-10-25	Initiated	Goldman	Buy	$97
Jul-07-25	Initiated	Leerink Partners	Outperform	$88
Apr-07-25	Upgrade	BofA Securities	Neutral → Buy	$63
Mar-05-25	Resumed	Stifel	Buy	$78
Jan-02-25	Initiated	Jefferies	Buy	$80
Dec-20-24	Initiated	Oppenheimer	Outperform	$76
Oct-21-24	Initiated	Guggenheim	Buy	$70
Sep-18-24	Initiated	H.C. Wainwright	Buy	$64
Sep-17-24	Initiated	JMP Securities	Mkt Outperform	$64
May-08-24	Downgrade	BofA Securities	Buy → Neutral	$49 → $42
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$29 → $55
Aug-01-23	Upgrade	BofA Securities	Neutral → Buy	$22 → $27
Jan-18-23	Resumed	Canaccord Genuity	Buy	$52
Aug-08-22	Upgrade	Goldman	Neutral → Buy	$28
Aug-05-22	Upgrade	BofA Securities	Underperform → Neutral	$8 → $20
Jun-17-22	Reiterated	Needham	Buy	$40 → $25
Mar-02-22	Resumed	Stifel	Buy	$23
Feb-17-22	Upgrade	Ladenburg Thalmann	Neutral → Buy	$15

Show Previous Ratings

Feb-05-26 08:00AM	Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit (GlobeNewswire)
Feb-02-26 06:12AM	This High-Flying Growth Stock Is Hiding in Plain Sight (Motley Fool) +6.31%
Jan-22-26 06:15AM	Sutro Biopharma (STRO) Soars 5.9%: Is Further Upside Left in the Stock? (Zacks)
Jan-09-26 08:00AM	Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones (GlobeNewswire)
Dec-12-25 05:18AM	Praxis tees up another approval filing; Geron turns to layoffs (BioPharma Dive)
01:49PM	Loading…
Dec-11-25 01:49PM	Rhythm Pharma Hits Record High On Unexpected Obesity-Tied Win (Investor's Business Daily) +12.26%
07:30AM	Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome (GlobeNewswire)
Dec-10-25 04:01PM	Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome (GlobeNewswire)
Dec-04-25 11:10AM	The Biotech Industry Is Healthier Than Investors Think. These Are the Stocks to Watch. (Barrons.com)
Nov-25-25 09:36AM	Brinker upgraded, Coinbase downgraded: Wall Street's top analyst calls (The Fly)
Nov-10-25 07:00AM	Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek 2025 (GlobeNewswire)
Nov-07-25 07:30AM	Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE (setmelanotide) for Patients with Acquired Hypothalamic Obesity (GlobeNewswire)
Nov-05-25 04:01PM	Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program (GlobeNewswire) -5.26%
Nov-04-25 04:03PM	Rhythm Pharmaceuticals Inc (RYTM) Q3 2025 Earnings Call Highlights: Revenue Growth and ... (GuruFocus.com) -7.69%
08:15AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Loading…
07:00AM	Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update (GlobeNewswire)
Oct-29-25 10:00AM	Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-28-25 10:00AM	Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-21-25 04:01PM	Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 (GlobeNewswire)
Oct-09-25 01:38PM	Rhythm Pharma Stock Gears Up For Its Next Move (Investor's Business Daily)
Oct-03-25 08:48AM	Should You Expect Robust Growth Potential for Rhythm Pharmaceuticals (RYTM) Ahead? (Insider Monkey)
Sep-27-25 08:02AM	Nvidia, These Other AI Plays Lead 5 Stocks Near Buy Points (Investor's Business Daily)
Sep-21-25 10:45AM	2 Under-the-Radar Stocks That Could Soar (Motley Fool)
Sep-01-25 01:04AM	Citizens JMP Keeps Market Outperform Rating on Rhythm Pharmaceuticals (RYTM) (Insider Monkey)
Aug-28-25 11:50PM	FDA Accepts a New Drug Application From Rhythm Pharmaceuticals (RYTM) (Insider Monkey)
Aug-27-25 04:01PM	Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-20-25 04:01PM	Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity (GlobeNewswire)
Aug-05-25 08:10AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update (GlobeNewswire)
Aug-01-25 06:46AM	Canaccord Genuity Maintained a Buy Rating on Rhythm Pharmaceuticals (RYTM) (Insider Monkey)
10:00AM	Loading…
Jul-30-25 10:00AM	Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jul-29-25 10:00AM	Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to Decline (Zacks)
Jul-22-25 04:01PM	Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025 (GlobeNewswire)
Jul-21-25 09:45AM	Should You Invest in This Under-the-Radar Weight Loss Stock? (Motley Fool)
Jul-12-25 06:00PM	Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025 (GlobeNewswire)
05:30AM	Investing.coms stocks of the week (Investing.com)
Jul-10-25 11:09AM	RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data (Zacks)
07:38AM	Rhythms stock climbs on encouraging Phase II obesity drug data (Clinical Trials Arena)
06:21AM	Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire)
Jul-09-25 04:16PM	Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire) +36.63%
11:33AM	Rhythm Pharma Surges To Record High On 'Impressive' Results In Obesity (Investor's Business Daily)
08:00AM	Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity (GlobeNewswire)
Jul-08-25 04:01PM	Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity (GlobeNewswire)
Jun-25-25 08:00AM	Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025 (GlobeNewswire)
Jun-06-25 04:00PM	This IBD 50 Biotech's Got 'Rhythm' And Flashes 3 Telltale Clues (Investor's Business Daily)
Jun-05-25 08:06AM	This IBD 50 Biotech's Got 'Rhythm' - And Flashes 3 Telltale Clues (Investor's Business Daily)
May-29-25 12:50PM	Funds Go All In On Weight-Loss Leader; Stock Nears Highs (Investor's Business Daily)
May-14-25 08:00AM	Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program (GlobeNewswire)
May-08-25 03:10AM	Rhythm Pharmaceuticals Inc (RYTM) Q1 2025 Earnings Call Highlights: Strong IMCIVREE Sales and ... (GuruFocus.com) -6.05%
May-07-25 03:22PM	Rhythm pharmaceuticals outlines Q3 2025 filing for acquired hypothalamic obesity treatment (Seeking Alpha)
03:21PM	Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2025 Earnings Call Transcript (Seeking Alpha)
08:10AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update (GlobeNewswire)
May-06-25 08:00AM	Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-01-25 10:01AM	Analysts Estimate Wave Life Sciences (WVE) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-30-25 10:01AM	Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know (Zacks)
Apr-25-25 09:40AM	Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last? (Zacks)
Apr-23-25 08:00AM	Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025 (GlobeNewswire)
Apr-08-25 03:42PM	Rhythm Pharmaceuticals Stock Earns RS Rating Upgrade (Investor's Business Daily) +5.04%
01:38PM	Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder (Seeking Alpha)
12:10PM	5 Stocks in Nasdaq ETF Fueling Index's Big Comeback Since 2008 (Zacks)
11:21AM	RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study (Zacks)
07:09AM	Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains? (Zacks)
Apr-07-25 04:09PM	This Obesity Drug Just Crushed Expectations -- And Sent One Biotech Stock Soaring 14.5% (GuruFocus.com) +17.06%
12:30PM	Rhythm seeks market expansion for Imcivree following Phase III victory (Clinical Trials Arena)
12:23PM	Rhythm Pharmaceuticals Weight Loss Drug Study Shows Significant BMI Reduction For Rare Type Of Obesity Disorder (Benzinga)
07:51AM	Obesity drug data helps Rhythm defy market slide (BioPharma Dive)
07:00AM	Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity (GlobeNewswire)
Apr-06-25 12:00PM	Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity (GlobeNewswire)
Mar-20-25 04:55PM	Is Rhythm Pharmaceuticals (RYTM) a Worst High-Risk High-Reward Growth Stock to Buy? (InsiderMonkey)
04:01PM	Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE (setmelanotide) in China with Termination of Agreement with RareStone Ltd. (GlobeNewswire)
Mar-19-25 04:23PM	Rhythm Pharmaceuticals gets Orphan Drug status for its hypothalamic obesity treatment in Japan (SeekingAlpha) +5.58%
04:01PM	Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan (GlobeNewswire)
Mar-18-25 07:00AM	Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration (GlobeNewswire)
Feb-27-25 02:07AM	Rhythm Pharmaceuticals Inc (RYTM) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
12:38AM	Q4 2024 Rhythm Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-26-25 08:25AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update (GlobeNewswire)
Feb-21-25 04:58PM	These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50 (Investor's Business Daily)
Feb-13-25 08:00AM	Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025 (GlobeNewswire)
Feb-05-25 08:00AM	Rhythm Pharmaceuticals to Present at Oppenheimer Annual Healthcare Life Sciences Conference in February (GlobeNewswire)
Jan-28-25 09:55AM	Wall Street Analysts Think Rhythm Pharmaceuticals (RYTM) Could Surge 26.36%: Read This Before Placing a Bet (Zacks)
Jan-22-25 08:50AM	Rhythm Pharmaceuticals (RYTM) Soars 5.5%: Is Further Upside Left in the Stock? (Zacks)
Jan-10-25 07:15AM	Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones (GlobeNewswire)
Jan-02-25 10:15AM	Jefferies starts Rhythm Pharmaceuticals with Buy on obesity potential (TipRanks) +7.31%
Dec-20-24 02:24PM	Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential (Benzinga)
02:15PM	Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE (setmelanotide) for Patients as Young as 2 Years Old (GlobeNewswire)
Dec-06-24 06:48AM	Rhythm Pharmaceuticals price target raised to $75 from $64 at JMP Securities (TipRanks)
Dec-03-24 06:00AM	Rhythm Pharmaceuticals Announces IMCIVREE (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old (GlobeNewswire)
Nov-18-24 12:02PM	Biotech Stock Attempts To End Losing Streak, Lands Back in Buy Zone (Investor's Business Daily)
07:00AM	Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide (GlobeNewswire)
Nov-13-24 06:30PM	Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology (GlobeNewswire) -6.23%
04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
Nov-07-24 02:29AM	Rhythm Pharmaceuticals Inc (RYTM) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-06-24 08:00AM	Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences (GlobeNewswire) +11.38%
Nov-05-24 05:10PM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +6.15%
04:01PM	Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update (GlobeNewswire)
Nov-04-24 04:01PM	Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek 2024 (GlobeNewswire) +8.12%
Oct-29-24 10:01AM	Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-24-24 06:00AM	Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome (GlobeNewswire)

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Smith Hunter C	Chief Financial Officer	Feb 05 '26	Sale	106.06	3,381	358,599	125,537	Feb 06 06:38 PM
Smith Hunter C	Chief Financial Officer	Feb 04 '26	Sale	105.99	3,247	344,145	128,918	Feb 06 06:38 PM
HUNTER SMITH	Officer	Feb 05 '26	Proposed Sale	107.97	18,406	1,987,296		Feb 05 04:30 PM
HUNTER SMITH	Officer	Feb 04 '26	Proposed Sale	108.29	3,247	351,618		Feb 04 04:21 PM
Cramer Pamela J.	Chief Human Resources Officer	Dec 11 '25	Option Exercise	27.35	3,350	91,622	24,164	Dec 15 04:30 PM
Cramer Pamela J.	Chief Human Resources Officer	Dec 11 '25	Sale	111.00	3,350	371,850	20,814	Dec 15 04:30 PM
PAMELA CRAMER	Officer	Dec 11 '25	Proposed Sale	104.77	3,350	350,980		Dec 11 04:25 PM
Cramer Pamela J.	Chief Human Resources Officer	Nov 20 '25	Option Exercise	27.35	3,350	91,622	24,164	Nov 24 04:15 PM
Cramer Pamela J.	Chief Human Resources Officer	Nov 20 '25	Sale	105.00	3,350	351,750	20,814	Nov 24 04:15 PM
PAMELA CRAMER	Officer	Nov 20 '25	Proposed Sale	103.15	3,350	345,552		Nov 20 04:23 PM
Cramer Pamela J.	Chief Human Resources Officer	Nov 07 '25	Option Exercise	12.36	19,351	239,184	40,165	Nov 12 04:30 PM
Cramer Pamela J.	Chief Human Resources Officer	Nov 10 '25	Option Exercise	6.80	3,515	23,902	24,329	Nov 12 04:30 PM
Cramer Pamela J.	Chief Human Resources Officer	Nov 07 '25	Sale	98.82	19,351	1,912,326	20,814	Nov 12 04:30 PM
Cramer Pamela J.	Chief Human Resources Officer	Nov 10 '25	Sale	100.00	3,515	351,500	20,814	Nov 12 04:30 PM
PAMELA CRAMER	Officer	Nov 10 '25	Proposed Sale	100.30	3,515	352,554		Nov 10 04:31 PM
PAMELA CRAMER	Officer	Nov 07 '25	Proposed Sale	98.49	19,351	1,905,880		Nov 07 04:38 PM
Shulman Joseph	Chief Technical Officer	Oct 30 '25	Option Exercise	30.66	9,748	298,874	18,257	Nov 03 04:30 PM
Shulman Joseph	Chief Technical Officer	Oct 30 '25	Sale	115.24	9,748	1,123,398	8,509	Nov 03 04:30 PM
Shulman Joseph	Chief Technical Officer	Oct 28 '25	Option Exercise	28.20	2,815	79,377	11,324	Oct 30 04:44 PM
Shulman Joseph	Chief Technical Officer	Oct 28 '25	Sale	115.01	2,815	323,750	8,509	Oct 30 04:44 PM
JOSEPH SHULMAN	Officer	Oct 30 '25	Proposed Sale	113.89	9,748	1,110,200		Oct 30 04:16 PM
JOSEPH SHULMAN	Officer	Oct 28 '25	Proposed Sale	111.55	2,815	314,013		Oct 28 04:17 PM
Shulman Joseph	Chief Technical Officer	Oct 16 '25	Option Exercise	30.18	14,437	435,711	22,946	Oct 20 04:30 PM
Shulman Joseph	Chief Technical Officer	Oct 16 '25	Sale	112.03	14,437	1,617,337	8,509	Oct 20 04:30 PM
JOSEPH SHULMAN	Officer	Oct 16 '25	Proposed Sale	109.35	14,437	1,578,686		Oct 16 04:20 PM
Shulman Joseph	Chief Technical Officer	Sep 02 '25	Option Exercise	30.25	16,781	507,574	25,290	Sep 04 04:30 PM
Shulman Joseph	Chief Technical Officer	Sep 02 '25	Sale	105.30	16,781	1,767,006	8,509	Sep 04 04:30 PM
JOSEPH SHULMAN	Officer	Sep 02 '25	Proposed Sale	103.15	16,781	1,730,960		Sep 02 04:41 PM
Shulman Joseph	Chief Technical Officer	Aug 21 '25	Option Exercise	27.35	4,188	114,542	12,697	Aug 25 08:59 PM
Shulman Joseph	Chief Technical Officer	Aug 21 '25	Sale	100.07	4,188	419,091	8,509	Aug 25 08:59 PM
JOSEPH SHULMAN	Officer	Aug 21 '25	Proposed Sale	98.70	4,188	413,356		Aug 21 04:45 PM
Smith Hunter C	Chief Financial Officer	Aug 12 '25	Option Exercise	6.88	24,611	169,324	141,526	Aug 14 06:48 PM
Smith Hunter C	Chief Financial Officer	Aug 13 '25	Option Exercise	6.88	3,477	23,922	120,392	Aug 14 06:48 PM
Smith Hunter C	Chief Financial Officer	Aug 12 '25	Sale	96.33	24,611	2,370,832	116,915	Aug 14 06:48 PM
Smith Hunter C	Chief Financial Officer	Aug 13 '25	Sale	96.00	3,477	333,792	116,915	Aug 14 06:48 PM
German Christopher Paul	Corporate Controller & CAO	Aug 12 '25	Option Exercise	28.39	1,500	42,585	1,922	Aug 14 06:47 PM
German Christopher Paul	Corporate Controller & CAO	Aug 12 '25	Sale	95.00	1,500	142,500	922	Aug 14 06:47 PM
Shulman Joseph	Chief Technical Officer	Aug 11 '25	Option Exercise	6.80	3,984	27,091	12,493	Aug 13 06:32 PM
Shulman Joseph	Chief Technical Officer	Aug 11 '25	Sale	90.08	3,984	358,891	8,509	Aug 13 06:32 PM
HUNTER SMITH	Officer	Aug 12 '25	Proposed Sale	94.31	28,088	2,648,979		Aug 12 04:28 PM
CHRISTOPHER PAUL GERMAN	Officer	Aug 12 '25	Proposed Sale	94.31	1,500	141,465		Aug 12 04:26 PM
JOSEPH SHULMAN	Officer	Aug 11 '25	Proposed Sale	91.98	3,984	366,448		Aug 11 04:22 PM
Cramer Pamela J.	Chief Human Resources Officer	Jul 29 '25	Sale	85.93	1,520	130,614	20,814	Jul 29 06:56 PM
Smith Hunter C	Chief Financial Officer	Jul 09 '25	Option Exercise	6.88	42,120	289,786	159,035	Jul 11 04:31 PM
Smith Hunter C	Chief Financial Officer	Jul 09 '25	Sale	80.48	42,120	3,389,756	116,915	Jul 11 04:31 PM
Shulman Joseph	Chief Technical Officer	Jul 09 '25	Option Exercise	6.80	7,969	54,189	16,478	Jul 11 04:30 PM
Shulman Joseph	Chief Technical Officer	Jul 09 '25	Sale	77.78	7,969	619,851	8,509	Jul 11 04:30 PM
German Christopher Paul	Corporate Controller & CAO	Jul 09 '25	Option Exercise	27.29	2,850	77,786	4,739	Jul 11 04:30 PM
German Christopher Paul	Corporate Controller & CAO	Jul 09 '25	Sale	80.75	3,817	308,217	922	Jul 11 04:30 PM
Cramer Pamela J.	Chief Human Resources Officer	Jul 09 '25	Option Exercise	13.43	15,572	209,153	34,781	Jul 11 04:30 PM
Cramer Pamela J.	Chief Human Resources Officer	Jul 09 '25	Sale	77.13	15,572	1,201,062	19,209	Jul 11 04:30 PM
CHRISTOPHER PAUL GERMAN	Officer	Jul 09 '25	Proposed Sale	65.14	3,817	248,639		Jul 09 04:17 PM
PAMELA CRAMER	Officer	Jul 09 '25	Proposed Sale	65.14	15,572	1,014,360		Jul 09 04:17 PM
HUNTER SMITH	Officer	Jul 09 '25	Proposed Sale	65.14	42,120	2,743,697		Jul 09 04:16 PM
JOSEPH J SHULMAN	Officer	Jul 09 '25	Proposed Sale	65.14	7,969	519,101		Jul 09 04:16 PM
Smith Hunter C	Chief Financial Officer	Jul 07 '25	Option Exercise	6.88	6,986	48,064	116,915	Jul 08 04:30 PM
Garfield Alastair	Chief Scientific Officer	Jul 02 '25	Sale	64.81	1,319	85,483	3,126	Jul 03 05:12 PM
German Christopher Paul	Corporate Controller & CAO	Jun 10 '25	Option Exercise	17.97	1,069	19,210	3,958	Jun 12 04:50 PM
German Christopher Paul	Corporate Controller & CAO	Jun 10 '25	Sale	67.19	2,069	139,016	1,889	Jun 12 04:50 PM
Cramer Pamela J.	Chief Human Resources Officer	Jun 06 '25	Option Exercise	6.80	7,031	47,811	26,240	Jun 10 04:45 PM
Cramer Pamela J.	Chief Human Resources Officer	Jun 06 '25	Sale	68.05	7,031	478,435	19,209	Jun 10 04:45 PM
CHRISTOPHER PAUL GERMAN	Officer	Jun 10 '25	Proposed Sale	66.72	2,069	138,044		Jun 10 04:21 PM
PAMELA CRAMER	Officer	Jun 06 '25	Proposed Sale	66.18	7,031	465,312		Jun 06 04:25 PM
MCGIRR DAVID W J	Director	Jun 03 '25	Option Exercise	4.59	65,431	300,328	68,431	Jun 05 04:16 PM
MCGIRR DAVID W J	Director	Jun 03 '25	Sale	65.22	65,431	4,267,494	3,000	Jun 05 04:16 PM
Meeker David P	President and CEO	Jun 03 '25	Option Exercise	4.59	43,620	200,216	245,445	Jun 05 04:16 PM
Meeker David P	President and CEO	Jun 03 '25	Sale	65.05	43,620	2,837,333	201,825	Jun 05 04:16 PM
DAVID W MCGIRR	Director	Jun 03 '25	Proposed Sale	63.66	65,431	4,165,337		Jun 03 04:27 PM
DAVID MEEKER	Director	Jun 03 '25	Proposed Sale	63.66	43,621	2,776,913		Jun 03 04:27 PM
Smith Hunter C	Chief Financial Officer	May 30 '25	Option Exercise	6.88	23,400	160,992	133,329	Jun 03 04:15 PM
Smith Hunter C	Chief Financial Officer	May 30 '25	Sale	61.41	23,400	1,437,010	109,929	Jun 03 04:15 PM
HUNTER SMITH	Officer	May 30 '25	Proposed Sale	61.88	23,400	1,447,992		May 30 04:35 PM
Cramer Pamela J.	Chief Human Resources Officer	Apr 29 '25	Option Exercise	6.80	7,031	47,811	26,240	May 01 04:53 PM
Cramer Pamela J.	Chief Human Resources Officer	Apr 29 '25	Sale	65.09	7,031	457,663	19,209	May 01 04:53 PM
Mazabraud Yann	EVP, Head of International	Apr 29 '25	Sale	65.08	6,745	438,946	37,655	May 01 04:52 PM
YANN MAZZABRAUD	Officer	Apr 29 '25	Proposed Sale	64.41	6,745	434,445		Apr 29 04:21 PM
PAMELA CRAMER	Officer	Apr 29 '25	Proposed Sale	64.41	7,031	452,867		Apr 29 04:20 PM
Cramer Pamela J.	Chief Human Resources Officer	Apr 08 '25	Option Exercise	13.43	20,760	278,853	39,969	Apr 10 05:17 PM
Cramer Pamela J.	Chief Human Resources Officer	Apr 08 '25	Sale	60.14	20,760	1,248,490	19,209	Apr 10 05:17 PM
Mazabraud Yann	EVP, Head of International	Apr 08 '25	Sale	60.99	17,750	1,082,497	22,620	Apr 10 05:16 PM
PAMELA CRAMER	Officer	Apr 08 '25	Proposed Sale	54.96	20,760	1,140,970		Apr 08 04:18 PM
YANN MAZZABRAUD	Officer	Apr 08 '25	Proposed Sale	54.96	17,750	975,540		Apr 08 04:16 PM
German Christopher Paul	Corporate Controller & CAO	Mar 21 '25	Sale	54.23	344	18,655	2,889	Mar 24 05:47 PM
Mazabraud Yann	EVP, Head of International	Mar 14 '25	Option Exercise	22.28	75,000	1,671,000	115,370	Mar 18 09:16 PM
Mazabraud Yann	EVP, Head of International	Mar 14 '25	Sale	51.48	75,000	3,861,272	40,370	Mar 18 09:16 PM
YANN MAZZABRAUD	Officer	Mar 14 '25	Proposed Sale	50.24	75,000	3,768,000		Mar 14 04:21 PM
Smith Hunter C	Chief Financial Officer	Feb 19 '25	Sale	57.22	2,215	126,742	109,929	Feb 19 09:50 PM
Shulman Joseph	Chief Technical Officer	Feb 19 '25	Sale	57.22	1,228	70,266	8,509	Feb 19 09:49 PM
Meeker David P	President and CEO	Feb 19 '25	Sale	57.22	9,896	566,249	201,281	Feb 19 09:48 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 19 '25	Sale	57.22	2,035	116,443	5,858	Feb 19 09:46 PM
German Christopher Paul	Corporate Controller & CAO	Feb 19 '25	Sale	57.22	635	36,335	2,070	Feb 19 09:45 PM
Cramer Pamela J.	Chief Human Resources Officer	Feb 19 '25	Sale	57.22	982	56,190	19,209	Feb 19 09:43 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 13 '25	Sale	58.00	1,205	69,890	2,393	Feb 14 04:55 PM
JENNIFER KAYDEN LEE	Officer	Feb 13 '25	Proposed Sale	57.64	1,205	69,456		Feb 13 04:31 PM

Open in Screener

INSM

Insmed Inc

Feb 12 • 03:35PM ET

147.03

-1.40 -0.94 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BIIB REGN GILD RARE NBIX UTHR SRPT EXEL BMRN

| Held by: VTI QQQ VB VO VXF VUG VBK IBB IWP VOT

Index	NDX	P/E	-	EPS (ttm)	-6.18	Insider Own	1.37%	Shs Outstand	212.58M	Perf Week	-2.65%
Market Cap	31.36B	Forward P/E	-	EPS next Y	-2.46	Insider Trans	-21.20%	Shs Float	210.34M	Perf Month	-10.19%
Enterprise Value	30.42B	PEG	-	EPS next Q	-1.06	Inst Own	103.59%	Short Float	5.56%	Perf Quarter	-24.09%
Income	-1.18B	P/S	70.15	EPS this Y	-4.66%	Inst Trans	0.94%	Short Ratio	3.85	Perf Half Y	19.66%
Sales	447.02M	P/B	33.06	EPS next Y	57.75%	ROA	-53.64%	Short Interest	11.70M	Perf YTD	-15.52%
Book/sh	4.45	P/C	18.67	EPS next 5Y	-	ROE	-165.69%	52W High	212.75 -30.89%	Perf Year	84.71%
Cash/sh	7.88	P/FCF	-	EPS past 3/5Y	-12.84% -13.12%	ROIC	-70.54%	52W Low	60.40 143.43%	Perf 3Y	649.39%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	24.50% 21.66%	Gross Margin	75.35%	Volatility	3.35% 3.98%	Perf 5Y	251.91%
Dividend TTM	-	EV/Sales	68.06	EPS Y/Y TTM	-11.26%	Oper. Margin	-221.53%	ATR (14)	6.24	Perf 10Y	1025.80%
Dividend Ex-Date	-	Quick Ratio	4.34	Sales Y/Y TTM	30.34%	Profit Margin	-264.83%	RSI (14)	32.03	Recom	1.18
Dividend Gr. 3/5Y	- -	Current Ratio	4.63	EPS Q/Q	-37.66%	SMA20	-5.39%	Beta	1.13	Target Price	215.15
Payout	-	Debt/Eq	0.79	Sales Q/Q	52.36%	SMA50	-14.69%	Rel Volume	0.43	Prev Close	148.43
Employees	1271	LT Debt/Eq	0.77	Earnings	Feb 19 BMO	SMA200	6.60%	Avg Volume	3.04M	Price	147.03
IPO	Feb 15, 1991	Option/Short	Yes / Yes	EPS/Sales Surpr.	-31.72% 23.30%	Trades		Volume	1,229,317	Change	-0.94%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Initiated	Barclays	Overweight	$231
Jan-23-26	Initiated	Roth Capital	Buy	$212
Dec-19-25	Resumed	Truist	Buy	$202
Dec-04-25	Initiated	Rothschild & Co Redburn	Buy	$263
Oct-28-25	Resumed	Cantor Fitzgerald	Overweight	$192
Oct-20-25	Initiated	Wells Fargo	Overweight	$171
Aug-20-25	Initiated	William Blair	Outperform
Aug-13-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$126
May-13-25	Initiated	Jefferies	Buy	$105
Feb-25-25	Initiated	RBC Capital Mkts	Outperform	$100
Apr-23-24	Initiated	Truist	Buy	$48
Feb-15-24	Initiated	Wolfe Research	Outperform	$42
Dec-08-23	Initiated	Wells Fargo	Overweight	$55
Nov-20-23	Resumed	JP Morgan	Overweight	$36
Jul-26-23	Initiated	Guggenheim	Buy	$50
Dec-09-22	Initiated	Mizuho	Buy	$28
Dec-07-22	Initiated	Barclays	Overweight	$37
Nov-18-22	Initiated	BofA Securities	Buy	$39
Apr-27-22	Initiated	Goldman	Buy	$56
Dec-06-21	Initiated	JP Morgan	Overweight	$45

Show Previous Ratings

Today 10:00AM	Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-05-26 07:00AM	Insmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026 (PR Newswire)
Feb-02-26 01:30AM	The Druckenmiller Connection: Meet the Man Behind Bessent and Warsh (Barrons.com)
Jan-28-26 07:00AM	Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress (PR Newswire)
Jan-23-26 07:50AM	Here Are Fridays Top Wall Street Analyst Research Calls: Applied Materials, e.l.f. Beauty, Fortinet, Freeport MacMoRan, Procter & Gamble, Spotify, and More (24/7 Wall St.)
01:04AM	Loading…
Jan-19-26 01:04AM	Analyst Weighs Patent Cliff Risks Against Insmed's (INSM) Growth Story (Insider Monkey)
Jan-12-26 07:08PM	Insmed CEO Will Lewis talks its rare disease drug pipeline (CNBC TV)
09:32AM	INSM Stock Jumps on 2025 Preliminary Sales, 2026 Goals Announced (Zacks)
Jan-09-26 04:38PM	S&P 500 Rallies to a New Record High on US Economic Optimism (Barchart)
11:19AM	Healthcare dealmakers head to San Francisco hoping for megamergers in 2026 (Reuters)
10:58AM	Insmed Maps Aggressive 2026 As Newly Approved Lung Disease Drug Gains Traction, Pipeline Advances (Benzinga)
09:44AM	Stock Market Today: Dow Up After Surprise Jobs Data; Trump Tariff Ruling Looms (Live Coverage) (Investor's Business Daily)
07:00AM	Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
06:28AM	Insmeds ginormous lung drug sales; J&Js US pricing deal (BioPharma Dive)
Jan-08-26 07:20AM	Jim Cramer on Insmed: "This One Is Worth Keeping an Eye On" (Insider Monkey)
10:19AM	Loading…
Jan-05-26 10:19AM	Stock Market Today: Dow Jumps After U.S. Ousts Maduro; Energy Shines, Nvidia Rallies Ahead (Live Coverage) (Investor's Business Daily)
09:01AM	Bet on These 3 Small-Cap ETFs to Ride the January Effect (Zacks)
Jan-02-26 08:15AM	INSM Stock Up 78% in 6 Months: Here's What You Need to Know (Zacks)
07:00AM	Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-31-25 09:01AM	Ultragenyx (RARE) Moves 15.5% Higher: Will This Strength Last? (Zacks)
Dec-30-25 04:31PM	Stocks Fall Slightly in Thin Holiday Trade (Barchart)
11:06AM	Stocks Slip as Bond Yields Rise (Barchart)
Dec-26-25 02:33AM	The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar (Zacks)
Dec-24-25 10:51AM	4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow (Zacks)
Dec-18-25 06:15PM	Mizuho's Jared Holz talks Insmed sinking double digits on sinus drug trial news (CNBC TV) -16.08%
04:33PM	Stocks Settle Higher on Upbeat Tech Outlook and Cooling Inflation (Barchart)
04:15PM	The 'Worst-Case Scenario' Why Insmed Just Reversed After A 181% Six-Month Sprint (Investor's Business Daily)
04:13PM	These Stocks Moved the Most Today: Micron, DJT, Accenture, Tilray, Lululemon, Medline, Rivian, and More (Barrons.com)
03:13PM	These Stocks Are Moving the Most Today: Micron, DJT, Accenture, Tilray, Lululemon, Medline, Rivian, and More (Barrons.com)
07:59AM	INSM Stock Plummets on Sinus Study Failure, Adds New Pipeline Asset (Zacks)
07:12AM	Loading…
07:12AM	Insmed Stock Plummets 19%. This Is What Sparked the Selloff. (Barrons.com)
06:10AM	These Stocks Are Moving the Most Today: Micron, Sandisk, Lululemon, Insmed, Rivian, PayPal, and More (Barrons.com)
06:02AM	Insmeds win streak ends as top drug fails study in chronic nasal condition (BioPharma Dive)
Dec-17-25 04:01PM	Insmed Provides Clinical and Business Update (PR Newswire)
Dec-15-25 12:15PM	MicroStrategy retains place in key index despite delisting threats (TheStreet)
09:11AM	Western Digital stock rises after inclusion in Nasdaq-100 Index (Investing.com)
07:03AM	200% Surge? These 6 Stocks Just Crashed the Nasdaq 100 Party (GuruFocus.com)
Dec-13-25 11:04AM	Walmart was too late for a Nasdaq-100 spot - but these 6 stocks made the cut (MarketWatch)
Dec-12-25 08:21PM	Bitcoin hoarding company Strategy remains in Nasdaq 100 (Reuters)
Dec-11-25 10:11AM	Crypto Market 2026 Predictions: Which Coins Will 10x and Which Will Crash? (24/7 Wall St.)
10:11AM	Billionaire Stanley Druckenmiller is Betting $1.2 Billion in These 3 Stocks (24/7 Wall St.)
Dec-10-25 11:30AM	Immunovant (IMVT) Down 0.6% Since Last Earnings Report: Can It Rebound? (Zacks)
Dec-04-25 11:30AM	Why Is Amgen (AMGN) Up 8% Since Last Earnings Report? (Zacks)
07:00AM	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Nov-30-25 03:14AM	30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks (Motley Fool)
Nov-28-25 10:07AM	Biotechs Are On A Big Run, And Two Stocks Have Buy Points (Investor's Business Daily)
Nov-25-25 07:35AM	Insmed (INSM) Rose Following Drug Approval (Insider Monkey)
Nov-24-25 12:38PM	This Investor Beat the Market for 3 Decades Without a Single Losing Year. 3 Stocks Hes Buying Now. (24/7 Wall St.)
Nov-20-25 03:45PM	These 15 stocks are still showing momentum - and a market-beating edge (MarketWatch)
Nov-19-25 10:59AM	Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri (Zacks)
05:03AM	Insmed receives EC approval for Brinsupri to treat NCFB (Pharmaceutical Business Review)
Nov-18-25 11:06AM	European Commission Approves BRINSUPRI (brensocatib) as the First and Only Treatment To Date Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union (PR Newswire)
11:00AM	European Commission Approves BRINSUPRI (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union (PR Newswire)
Nov-17-25 10:10AM	Here's What Lifted Insmed Incorporated (INSM) in Q3 (Insider Monkey)
Nov-13-25 07:00AM	Insmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good (PR Newswire)
Nov-05-25 07:00AM	Insmed To Present at November and December 2025 Investor Conferences (PR Newswire)
Nov-03-25 07:06PM	Latest read on rare disease gene therapy from Insmed CEO Will Lewis (CNBC TV)
09:16AM	Approval of Brinsupri Lifted Insmed Incorporated (INSM) in Q3 (Insider Monkey)
Oct-31-25 10:03AM	Insmed (INSM) Hits All-Time High as Firm Posts Highly Optimistic Outlook (Insider Monkey)
08:58AM	Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake (Zacks)
Oct-30-25 04:21PM	Insmed Inc (INSM) Q3 2025 Earnings Call Highlights: Strong Launch for Brin Suri and Robust ... (GuruFocus.com) +16.33%
04:12PM	Insmed Screams To A 25-Year High, While IBD 50's Argenx Slides (Investor's Business Daily)
08:46AM	Insmed Catapults While IBD 50's Argenx Creeps Higher On Bullish Reports (Investor's Business Daily)
08:20AM	Insmed (INSM) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
07:17AM	Insmed: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
05:08AM	Apple and Amazon headline earnings slate (MarketWatch)
04:29AM	Stock Market Today: Dow, S&P 500 and Nasdaq hover near record highs after U.S.-China trade deal, while Meta stock dives but Alphabet pops on earnings; Apple and Amazon results on tap; Treasury yields up on December rate-cut pushback. (MarketWatch)
Oct-29-25 04:14PM	United Therapeutics Rockets 10% On Growing Enthusiasm For Its Top Drug (Investor's Business Daily)
09:55AM	The Mixed Results For United Therapeutics' Bread-And-Butter Drug (Investor's Business Daily)
09:15AM	Gear Up for Insmed (INSM) Q3 Earnings: Wall Street Estimates for Key Metrics (Zacks)
Oct-27-25 10:00AM	Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-23-25 04:05PM	Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List (PR Newswire)
10:00AM	Analysts Estimate Insmed (INSM) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-17-25 07:00AM	CHMP Recommends EU Approval of BRINSUPRI (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis (PR Newswire)
Oct-16-25 07:00AM	Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025 (PR Newswire)
Oct-15-25 08:07AM	Does Insmed Incorporated (INSM) Have a Promising Pipeline? (Insider Monkey)
07:00AM	Insmed to Host Third-Quarter 2025 Financial Results Conference Call on Thursday, October 30, 2025 (PR Newswire)
Oct-13-25 05:30AM	Why Biotech's Rally Can Last This Time (The Wall Street Journal)
Oct-08-25 10:30AM	This Strong Buy Stock Is Trading at New 20-Year Highs (Barchart)
Oct-03-25 05:24PM	Top Stock Reports for AMD, Abbott & Micron Technology (Zacks)
Oct-02-25 09:44AM	Ohio Retirement Fund Invests in Insmed Incorporated (INSM) (Insider Monkey)
Oct-01-25 10:40AM	Is IPF the Next Big Market Opportunity for United Therapeutics? (Zacks)
Sep-30-25 12:32PM	Insmed Incorporated (INSM) Rallies After FDA Approves Brinsupri, Shares Jump 9% (Insider Monkey)
Sep-27-25 12:58AM	RBC Capital Remains Bullish on Insmed Incorporated (INSM) (Insider Monkey)
Sep-22-25 07:00AM	Insmed to Present Multiple Abstracts at the European Respiratory Society Congress 2025 (PR Newswire)
Sep-12-25 08:09AM	Insmed (INSM) Reported Impressive Results from the Phase 2 Trial Of Its Inhalation Powder (Insider Monkey)
Sep-05-25 05:11PM	Top Analyst Reports for Microsoft, Amazon.com & Philip Morris (Zacks)
07:00AM	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Sep-04-25 09:42AM	Insmed scores pivotal win in bronchiectasis with FDA approval of Brinsupri (Pharmaceutical Technology)
Sep-03-25 01:48PM	UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals (Zacks)
Sep-02-25 04:09PM	Why United Therapeutics Catapulted 33%, Pulling Insmed, Liquidia With It (Investor's Business Daily) +6.76%
09:34AM	Why United Therapeutics Just Catapulted 35%, Pulling Insmed, Liquidia With It (Investor's Business Daily)
01:04AM	What Does Wall Street Think About Insmed Incorporated (INSM)? (Insider Monkey)
Aug-27-25 04:32PM	Bloomberg 500 (B500) Index Adds Sixteen Securities Following Semi-Annual Reconstitution (PR Newswire)
Aug-22-25 05:11AM	Magazine: Big biopharma take on the ADC challenge (Pharmaceutical Technology)
Aug-21-25 07:00AM	Insmed To Present at September Investor Conferences (PR Newswire)
Aug-19-25 01:21PM	Josh Brown's Best Stocks in the Market: Insmed (CNBC TV)
10:15AM	This Strong Buy Pharma Stock Is Surging to New Highs (Barchart)
Aug-14-25 02:05PM	Mizuho's Jared Holz on how to play the underperforming health care sector (CNBC TV)

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lewis William	Chair and CEO	Feb 09 '26	Option Exercise	24.94	10,699	266,840	314,581	Feb 11 04:42 PM
Lewis William	Chair and CEO	Feb 09 '26	Sale	147.79	13,396	1,979,764	301,185	Feb 11 04:42 PM
William Lewis	Officer	Feb 09 '26	Proposed Sale	147.79	13,396	1,979,774		Feb 09 05:32 PM
Flammer Martina M.D.	Chief Medical Officer	Feb 05 '26	Sale	152.44	869	132,470	83,243	Feb 06 04:18 PM
Martina Flammer	Officer	Feb 05 '26	Proposed Sale	152.43	869	132,462		Feb 05 05:12 PM
Adsett Roger	Chief Operating Officer	Feb 03 '26	Sale	156.17	791	123,530	106,810	Feb 04 04:20 PM
Bonstein Sara	Chief Financial Officer	Feb 03 '26	Sale	156.34	748	116,942	79,758	Feb 04 04:19 PM
Lewis William	Chair and CEO	Feb 03 '26	Sale	156.34	3,009	470,427	303,882	Feb 04 04:17 PM
Smith Michael Alexander	Chief Legal Officer	Feb 03 '26	Sale	156.27	640	100,013	56,397	Feb 04 04:15 PM
Flammer Martina M.D.	Chief Medical Officer	Feb 02 '26	Option Exercise	65.72	7,982	524,577	92,889	Feb 04 04:15 PM
Flammer Martina M.D.	Chief Medical Officer	Feb 02 '26	Sale	154.59	7,982	1,233,959	84,907	Feb 04 04:15 PM
Flammer Martina M.D.	Chief Medical Officer	Feb 03 '26	Sale	155.77	795	123,837	84,112	Feb 04 04:15 PM
Roger Adsett	Officer	Feb 03 '26	Proposed Sale	156.16	791	123,526		Feb 03 05:04 PM
Michael Smith	Officer	Feb 03 '26	Proposed Sale	156.27	640	100,012		Feb 03 05:02 PM
William Lewis	Officer	Feb 03 '26	Proposed Sale	156.33	3,009	470,412		Feb 03 04:58 PM
Martina Flammer	Officer	Feb 03 '26	Proposed Sale	155.77	795	123,837		Feb 03 04:56 PM
Sara Bonstein	Officer	Feb 03 '26	Proposed Sale	156.33	748	116,938		Feb 03 04:55 PM
Martina Flammer	Officer	Feb 02 '26	Proposed Sale	154.59	7,982	1,233,964		Feb 02 05:30 PM
Lewis William	Chair and CEO	Jan 20 '26	Option Exercise	24.94	10,699	266,840	317,590	Jan 22 04:28 PM
Lewis William	Chair and CEO	Jan 20 '26	Sale	158.93	10,699	1,700,411	306,891	Jan 22 04:28 PM
William Lewis	Officer	Jan 20 '26	Proposed Sale	158.93	10,699	1,700,420		Jan 20 04:33 PM
Lewis William	Chair and CEO	Jan 12 '26	Option Exercise	24.94	10,699	266,840	326,106	Jan 13 04:04 PM
Lewis William	Chair and CEO	Jan 12 '26	Sale	169.00	19,215	3,247,349	306,891	Jan 13 04:04 PM
Flammer Martina M.D.	Chief Medical Officer	Jan 09 '26	Sale	186.19	1,887	351,341	84,907	Jan 13 04:03 PM
William Lewis	Officer	Jan 12 '26	Proposed Sale	169.00	19,215	3,247,325		Jan 12 04:58 PM
Sara Bonstein	Officer	Jan 08 '26	Proposed Sale	174.17	1,447	252,023		Jan 08 05:40 PM
Martina Flammer	Officer	Jan 08 '26	Proposed Sale	174.17	5,138	894,885		Jan 08 05:35 PM
Martina Flammer	Officer	Jan 08 '26	Proposed Sale	173.90	1,660	288,674		Jan 08 05:28 PM
Roger Adsett	Officer	Jan 08 '26	Proposed Sale	174.17	2,059	358,616		Jan 08 05:23 PM
Adsett Roger	Chief Operating Officer	Jan 08 '26	Sale	174.17	2,059	358,616	107,601	Jan 08 05:22 PM
Adsett Roger	Chief Operating Officer	Jan 06 '26	Sale	173.33	1,429	247,689	110,462	Jan 08 05:22 PM
Adsett Roger	Chief Operating Officer	Jan 07 '26	Sale	175.07	802	140,406	109,660	Jan 08 05:22 PM
Bonstein Sara	Chief Financial Officer	Jan 07 '26	Sale	175.07	1,678	293,767	81,953	Jan 08 05:21 PM
Bonstein Sara	Chief Financial Officer	Jan 06 '26	Sale	173.33	1,517	262,942	83,631	Jan 08 05:21 PM
Bonstein Sara	Chief Financial Officer	Jan 08 '26	Sale	174.17	1,447	252,024	80,506	Jan 08 05:21 PM
Flammer Martina M.D.	Chief Medical Officer	Jan 06 '26	Option Exercise	26.43	8,570	226,505	103,324	Jan 08 05:20 PM
Flammer Martina M.D.	Chief Medical Officer	Jan 06 '26	Sale	173.80	10,185	1,770,134	93,139	Jan 08 05:20 PM
Flammer Martina M.D.	Chief Medical Officer	Jan 08 '26	Sale	174.07	4,911	854,851	86,794	Jan 08 05:20 PM
Flammer Martina M.D.	Chief Medical Officer	Jan 07 '26	Sale	175.84	1,434	252,155	91,705	Jan 08 05:20 PM
Lewis William	Chair and CEO	Jan 06 '26	Sale	173.33	4,096	709,960	320,987	Jan 08 05:20 PM
Lewis William	Chair and CEO	Jan 08 '26	Sale	174.17	3,223	561,350	315,407	Jan 08 05:20 PM
Lewis William	Chair and CEO	Jan 07 '26	Sale	175.07	2,357	412,640	318,630	Jan 08 05:20 PM
Smith Michael Alexander	Chief Legal Officer	Jan 06 '26	Sale	173.33	1,396	241,969	58,799	Jan 08 05:19 PM
Smith Michael Alexander	Chief Legal Officer	Jan 08 '26	Sale	174.17	1,053	183,401	57,037	Jan 08 05:19 PM
Smith Michael Alexander	Chief Legal Officer	Jan 07 '26	Sale	175.07	709	124,125	58,090	Jan 08 05:19 PM
Michael Smith	Officer	Jan 08 '26	Proposed Sale	174.17	1,053	183,401		Jan 08 05:19 PM
William Lewis	Officer	Jan 08 '26	Proposed Sale	174.17	3,223	561,349		Jan 08 05:08 PM
Roger Adsett	Officer	Jan 07 '26	Proposed Sale	175.07	802	140,406		Jan 07 05:10 PM
Michael Smith	Officer	Jan 07 '26	Proposed Sale	175.07	709	124,124		Jan 07 05:04 PM
William Lewis	Officer	Jan 07 '26	Proposed Sale	175.07	2,357	412,636		Jan 07 04:59 PM
Sara Bonstein	Officer	Jan 07 '26	Proposed Sale	175.17	1,678	293,935		Jan 07 04:42 PM
Martina Flammer	Officer	Jan 07 '26	Proposed Sale	175.84	1,434	252,154		Jan 07 04:42 PM
Sara Bonstein	Officer	Jan 06 '26	Proposed Sale	173.33	1,517	262,941		Jan 06 04:40 PM
Martina Flammer	Officer	Jan 06 '26	Proposed Sale	173.33	1,615	279,927		Jan 06 04:37 PM
Roger Adsett	Officer	Jan 06 '26	Proposed Sale	173.33	1,429	247,688		Jan 06 04:33 PM
Michael Smith	Officer	Jan 06 '26	Proposed Sale	173.33	1,396	241,969		Jan 06 04:26 PM
William Lewis	Officer	Jan 06 '26	Proposed Sale	173.33	4,096	709,959		Jan 06 04:20 PM
Flammer Martina M.D.	Chief Medical Officer	Jan 05 '26	Option Exercise	25.80	12,303	317,465	107,057	Jan 06 04:06 PM
Flammer Martina M.D.	Chief Medical Officer	Jan 05 '26	Sale	171.38	12,303	2,108,507	94,754	Jan 06 04:06 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	Jan 02 '26	Option Exercise	13.91	87,290	1,214,204	129,044	Jan 06 04:03 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	Jan 02 '26	Sale	175.20	87,290	15,293,422	41,754	Jan 06 04:03 PM
Martina Flammer	Officer	Jan 05 '26	Proposed Sale	171.39	20,873	3,577,423		Jan 05 04:33 PM
Stacey Nicole Schaeffer Orlov	Officer	Jan 02 '26	Proposed Sale	175.11	87,290	15,285,351		Jan 02 04:29 PM
Lewis William	Chair and CEO	Dec 18 '25	Option Exercise	24.94	10,699	266,840	314,610	Dec 19 04:12 PM
Lewis William	Chair and CEO	Dec 18 '25	Sale	166.97	10,699	1,786,457	303,911	Dec 19 04:12 PM
William Lewis	Officer	Dec 18 '25	Proposed Sale	166.97	10,699	1,786,437		Dec 18 04:45 PM
SHAROKY MELVIN MD	Director	Dec 05 '25	Sale	205.01	20,000	4,100,200	243,948	Dec 09 04:05 PM
MELVIN SHAROKY	DIRECTOR	Dec 05 '25	Proposed Sale	205.00	20,000	4,100,000		Dec 05 05:39 PM
Lewis William	Chair and CEO	Dec 04 '25	Option Exercise	24.94	10,699	266,840	314,610	Dec 05 04:11 PM
Lewis William	Chair and CEO	Dec 04 '25	Sale	205.62	10,699	2,199,915	303,911	Dec 05 04:11 PM
William Lewis	Officer	Dec 04 '25	Proposed Sale	205.59	10,699	2,199,583		Dec 04 05:10 PM
Flammer Martina M.D.	Chief Medical Officer	Dec 01 '25	Option Exercise	25.83	8,895	229,758	92,006	Dec 03 04:01 PM
Flammer Martina M.D.	Chief Medical Officer	Dec 01 '25	Sale	206.98	8,895	1,841,101	83,111	Dec 03 04:01 PM
Martina Flammer	Officer	Dec 01 '25	Proposed Sale	206.95	8,895	1,840,841		Dec 01 04:08 PM
ANDERSON ELIZABETH M	Director	Nov 24 '25	Sale	204.58	5,000	1,022,900	58,729	Nov 26 04:31 PM
ANDERSON ELIZABETH M	Director	Nov 24 '25	Proposed Sale	204.00	5,000	1,020,000		Nov 24 03:07 PM
LEE LEO	Director	Nov 17 '25	Sale	195.90	75,000	14,692,249	54,677	Nov 18 04:21 PM
ANDERSON ELIZABETH M	Director	Nov 14 '25	Sale	195.87	10,000	1,958,700	63,729	Nov 18 04:20 PM
Leo Lee	Director	Nov 17 '25	Proposed Sale	193.22	75,000	14,491,500		Nov 17 05:29 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	Nov 12 '25	Option Exercise	26.46	30,000	793,800	66,461	Nov 14 04:12 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	Nov 12 '25	Sale	194.00	30,000	5,820,061	36,461	Nov 14 04:12 PM
Flammer Martina M.D.	Chief Medical Officer	Nov 11 '25	Option Exercise	18.17	31,226	567,389	114,337	Nov 13 04:32 PM
Flammer Martina M.D.	Chief Medical Officer	Nov 11 '25	Sale	189.68	31,226	5,922,795	83,111	Nov 13 04:32 PM
ANDERSON ELIZABETH M	Director	Nov 13 '25	Proposed Sale	194.00	10,000	1,940,000		Nov 13 12:53 PM
Stacey Nicole Schaeffer Orlov	Officer	Nov 12 '25	Proposed Sale	194.51	30,000	5,835,300		Nov 12 04:57 PM
Martina Flammer	Officer	Nov 11 '25	Proposed Sale	189.64	31,226	5,921,820		Nov 12 08:28 AM
Smith Michael Alexander	Chief Legal Officer	Nov 03 '25	Option Exercise	23.75	27,130	644,338	82,032	Nov 05 04:08 PM
Smith Michael Alexander	Chief Legal Officer	Nov 03 '25	Sale	183.78	27,130	4,985,911	54,902	Nov 05 04:08 PM
Michael A Smith	Officer	Nov 03 '25	Proposed Sale	183.75	27,130	4,985,054		Nov 03 05:01 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	Sep 12 '25	Option Exercise	23.75	56,520	1,342,350	112,981	Sep 15 04:23 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	Sep 12 '25	Sale	145.45	76,520	11,129,927	36,461	Sep 15 04:23 PM
SHAROKY MELVIN MD	Director	Sep 12 '25	Sale	145.39	10,000	1,453,900	262,675	Sep 15 04:22 PM
Schaeffer Orlov S Nicole	Officer	Sep 12 '25	Proposed Sale	145.42	76,520	11,127,662		Sep 12 05:03 PM
SHAROKY MELVIN MD	Director	Sep 12 '25	Proposed Sale	145.00	10,000	1,450,000		Sep 12 03:55 PM
Smith Michael Alexander	Chief Legal Officer	Sep 02 '25	Option Exercise	30.46	12,780	389,279	79,174	Sep 04 05:26 PM
Smith Michael Alexander	Chief Legal Officer	Sep 02 '25	Sale	143.89	24,272	3,492,378	54,902	Sep 04 05:26 PM
Flammer Martina M.D.	Chief Medical Officer	Sep 02 '25	Option Exercise	23.40	186,648	4,366,788	269,759	Sep 04 05:24 PM
Flammer Martina M.D.	Chief Medical Officer	Sep 02 '25	Sale	144.34	186,648	26,941,272	83,111	Sep 04 05:24 PM
Flammer Martina M.D.	Officer	Sep 02 '25	Proposed Sale	144.31	186,648	26,935,498		Sep 02 04:49 PM
Smith Michael Alexander	Officer	Sep 02 '25	Proposed Sale	143.85	24,272	3,491,647		Sep 02 04:41 PM

RYTM

Rhythm Pharmaceuticals Inc

INSM

Insmed Inc

Upgrade your FINVIZ experience